Repligen
RGEN
A$183.39
Share price
-1.71%
Change (1 day)
-12.94%
Change (1 year)
Categories
Earnings for Repligen (RGEN)
Earnings in 2025 (TTM): -A$5.22 Million
According to Repligen 's latest financial reports the company's current earnings are A$0.65 Billion. In 2024 the company made an earning of -A$9.67 Million a decrease over its 2023 earnings that were of A$74.25 Million. The earnings displayed on this page is the company's Pretax Income.
Earnings history for Repligen from 1985 to 2025
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2025 (TTM)  | -A$5.22 Million | -46.04% |
| 2024 | -A$9.67 Million | -113.01% |
| 2023 | A$74.25 M | -78.01% |
| 2022 | A$0.33 B | 33.37% |
| 2021 | A$0.25 B | 131.52% |
| 2020 | A$0.10 B | 101.31% |
| 2019 | A$54.32 M | 25.93% |
| 2018 | A$43.13 M | 105.61% |
| 2017 | A$20.98 M | -11.46% |
| 2016 | A$23.69 M | 14.91% |
| 2015 | A$20.62 M | 20.26% |
| 2014 | A$17.14 M | -51.49% |
| 2013 | A$35.34 M | 90.98% |
| 2012 | A$18.5 M | |
| 2010 | A$0.26 M | -103.81% |
| 2009 | -A$7.04 Million | -223.84% |
| 2008 | A$5.67 M | |
| 2006 | -A$3.82 Million | 229.64% |
| 2005 | -A$1.16 Million | -89.16% |
| 2004 | -A$10.68 Million | -16.86% |
| 2003 | -A$12.85 Million | 88.72% |
| 2002 | -A$6.81 Million | -27.88% |
| 2001 | -A$9.44 Million | -1.74% |
| 2000 | -A$9.61 Million | 85.93% |
| 1999 | -A$5.17 Million | 159.16% |
| 1998 | -A$2 Million | 85.71% |
| 1997 | -A$1.08 Million | -70.83% |
| 1996 | -A$3.68 Million | -72.41% |
| 1995 | -A$13.34 Million | -60.63% |
| 1994 | -A$33.88 Million | 45.39% |
| 1993 | -A$23.3 Million | 39.45% |
| 1992 | -A$16.71 Million | -32.3% |
| 1991 | -A$24.68 Million | 6.62% |
| 1990 | -A$23.15 Million | 1577.78% |
| 1989 | -A$1.38 Million | -57.14% |
| 1988 | -A$3.22 Million | -362.5% |
| 1987 | A$1.22 M | -130.77% |
| 1986 | -A$3.99 Million | 136.36% |
| 1985 | -A$1.69 Million |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Novavax NVAX | A$0.78 B | -27,904.14% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | A$1.03 B | -36,846.87% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | A$0.81 B | -29,037.33% | 🇺🇸 USA |
 General Electric GE | A$13.50 B | -480,263.49% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | A$10.83 B | -385,277.11% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$9.36 B | -332,961.04% | 🇺🇸 USA |
 Pfizer PFE | A$15.84 B | -563,642.23% | 🇺🇸 USA |
 Bio-Techne TECH | A$0.26 B | -9,463.60% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | -A$0.13 Billion | 4,308.66% | 🇺🇸 USA |
 Charles River Laboratories
CRL | A$46.1 M | -1,739.29% | 🇺🇸 USA |